PDCD1 and skin squamous cell carcinoma: For patients with metastatic or locally advanced cSCC who are ineligible for curative surgery or RT, immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1), such as cemiplimab and pembrolizumab, have recently emerged as effective therapeutic options [8,9,10].